The identification of the CDKN2A mutation places patients at a high risk for pancreatic cancer, and their inclusion in screening programs improves the survival rate, as demonstrated by Vasen et al., who incorporated 19 patients with a CDKN2A mutation in such programs and found 13 patients with PC, 9 of them having a 5-year survival rate of 75% [73], higher than previously reported for patients with PC. The gene discussed is CDKN2A; the disease is familial pancreatic carcinoma.